Pulmonary Embolism

🕸️ Interactive Visualization How Clots Dissolve — snip the mesh or blast it with tPA Watch plasmin snip the fibrin mesh strand by strand and D-dimer wash away — then add a tPA clot-buster to blast it, or tranexamic acid to hold it shut. Launch →

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
Key Research Papers
Connections
Featured Videos

1. Overview

Pulmonary embolism (PE) is a potentially life-threatening condition caused by the occlusion of one or more pulmonary arteries, most commonly by thrombi originating in the deep veins of the lower extremities or pelvis. PE and deep vein thrombosis (DVT) are two manifestations of the same disease spectrum, collectively termed venous thromboembolism (VTE). The clinical severity ranges from asymptomatic subsegmental PE to massive PE with hemodynamic collapse and cardiac arrest. Prompt recognition and risk stratification are essential for appropriate management and to reduce mortality.

2. Epidemiology

PE is the third most common cause of cardiovascular mortality after myocardial infarction and stroke. It accounts for approximately 100,000–180,000 deaths annually in the United States. The annual incidence is estimated at 60–70 cases per 100,000 persons, with an increasing trend attributable to aging populations, greater use of computed tomography (CT) imaging, and rising prevalence of obesity and cancer. Deep vein thrombosis accompanies PE in up to 70% of confirmed cases. PE is responsible for 5–10% of all in-hospital deaths. Incidence doubles with each decade of life after age 40, and men have a slightly higher age-adjusted risk than women, though oral contraceptive use and pregnancy substantially elevate risk in premenopausal women.

3. Pathophysiology

The central pathophysiological consequence of PE is ventilation-perfusion (V/Q) mismatch. When a thrombus lodges in a pulmonary artery, the affected lung segment continues to be ventilated but receives no blood flow, creating dead space ventilation. Simultaneously, hypoxic vasoconstriction redistributes blood to non-obstructed zones, which may become overperfused relative to their ventilation, causing intrapulmonary shunting.

The hemodynamic impact depends on the extent of vascular obstruction and the underlying cardiopulmonary reserve. Obstruction of >30–50% of the pulmonary vascular bed in a previously healthy patient typically triggers acute right ventricular (RV) pressure overload. The RV dilates, interventricular septal bowing toward the left ventricle (the "D-sign") reduces left ventricular preload and output, potentially precipitating cardiogenic shock. Neurohumoral mediators — serotonin, histamine, thromboxane A2 — cause additional pulmonary vasoconstriction beyond mechanical obstruction. Elevated RV wall tension and reduced coronary perfusion pressure create a positive feedback loop of RV ischemia, further impairing RV function.

Hypoxemia results from multiple mechanisms: V/Q mismatch, intracardiac right-to-left shunting through a patent foramen ovale (present in ~25% of adults), low mixed venous oxygen saturation from reduced cardiac output, and surfactant depletion causing atelectasis in areas of prolonged ischemia.

4. Etiology and Risk Factors

The pathogenesis of venous thromboembolism is classically described by Virchow's Triad:

Venous stasis — Prolonged immobility (hospitalization, long-haul travel), paralysis, heart failure, obesity.
Endothelial injury — Trauma, surgery (especially orthopedic), central venous catheters, infection, inflammation.
Hypercoagulability — Inherited (Factor V Leiden mutation, Prothrombin G20210A mutation, Protein C/S deficiency, Antithrombin III deficiency) or acquired (antiphospholipid antibody syndrome, malignancy, pregnancy, oral contraceptives, heparin-induced thrombocytopenia, myeloproliferative neoplasms).

Major risk factors include:

Prior VTE (increases risk 3-fold)
Active malignancy (risk increased 4–7 fold; especially mucin-secreting adenocarcinomas)
Major surgery or trauma within 3 months
Hospitalization >3 days
Pregnancy and the postpartum period (up to 6 weeks)
Hormone replacement therapy or combined oral contraceptives
Long-distance travel (>8 hours)
Age >40 years
Obesity (body mass index (BMI) >30 kg/m²)

5. Clinical Presentation

The clinical presentation of PE is notoriously variable. Symptoms range from none (incidental finding) to sudden cardiac death. The classic triad of dyspnea, chest pain, and hemoptysis occurs in fewer than 20% of patients.

Common symptoms:

Dyspnea (most common; ~80% of symptomatic PE)
Pleuritic chest pain (40–50%)
Cough (20–30%)
Hemoptysis (10–15%)
Syncope or pre-syncope (massive PE)
Leg pain, swelling (suggestive of concurrent deep vein thrombosis)

Signs:

Tachycardia (most common sign; >100 bpm)
Tachypnea (>20 breaths/min)
Low-grade fever
Hypoxemia (O2 saturation <95%)
Hypotension or shock (massive PE)
Loud P2, right-sided S3/S4 gallop, elevated JVP (RV strain)

The Wells Score for PE stratifies pre-test probability:

Clinical signs/symptoms of deep vein thrombosis: 3 points
PE more likely than alternative diagnosis: 3 points
Heart rate >100 bpm: 1.5 points
Immobilization or surgery in past 4 weeks: 1.5 points
Previous DVT/PE: 1.5 points
Hemoptysis: 1 point
Malignancy: 1 point

Score ≤4: PE unlikely; >4: PE likely. The Revised Geneva Score and PERC Rule offer additional validated pre-test probability assessments.

6. Diagnosis

D-dimer: A highly sensitive (>95%) but nonspecific biomarker of fibrin degradation. Age-adjusted D-dimer threshold (age × 10 ng/mL in patients >50 years) improves specificity without sacrificing sensitivity. A negative D-dimer effectively excludes PE in low-to-moderate probability patients. Elevated in many conditions (infection, malignancy, pregnancy, post-surgery).

Computed tomography Pulmonary Angiography (CTPA): The diagnostic gold standard. Sensitivity 83–100%, specificity 89–98%. Provides direct visualization of thrombus, allows assessment of RV size (RV/LV ratio >0.9 indicates RV strain), and identifies alternative diagnoses. Preferred in patients with high pre-test probability or positive D-dimer.

Ventilation-Perfusion (V/Q) Scintigraphy: Preferred when CTPA is contraindicated (contrast allergy, severe renal impairment, pregnancy). A high-probability scan combined with high clinical probability confirms PE with >95% positive predictive value.

Echocardiography: Valuable in hemodynamically unstable patients where CTPA may not be feasible. RV dilation, septal flattening, tricuspid regurgitation, and the "60/60 sign" (PA acceleration time <60ms with tricuspid gradient <60 mmHg) suggest massive PE. Transesophageal echo may directly visualize central clot.

Cardiac biomarkers:

Troponin I/T: Elevated in RV myocardial injury; prognostic value for short-term mortality.
BNP/NT-proBNP: Reflects RV pressure overload; elevated levels associated with worse outcomes.

Lower extremity compression ultrasonography: When positive for proximal deep vein thrombosis in a patient with clinical suspicion, may preclude the need for CTPA and confirm the need for anticoagulation.

Pulmonary angiography: Invasive gold standard, now rarely used for diagnosis; reserved for catheter-directed interventions.

7. Treatment

Management is guided by risk stratification into massive (high-risk), submassive (intermediate-risk), and low-risk PE categories.

Anticoagulation

The cornerstone of PE treatment. Prevents thrombus propagation and allows endogenous fibrinolysis. Initiated empirically when clinical suspicion is high, before confirmatory imaging where appropriate.

Unfractionated heparin (UFH): Preferred in massive PE (rapid reversibility, enables transition to thrombolytics). Weight-based intravenous (IV) bolus (80 units/kg) followed by continuous infusion titrated to aPTT 60–100 seconds.
Low-molecular-weight heparin (LMWH): Enoxaparin 1 mg/kg SC every 12 hours. Preferred over UFH for non-massive PE due to predictable pharmacokinetics and lower HIT risk. The drug label calls for a reduced dose in severe kidney impairment (creatinine clearance <30 mL/min), because exposure to the drug rises markedly.
Direct oral anticoagulants (DOACs): Rivaroxaban (15 mg BID ×21 days, then 20 mg daily) or apixaban (10 mg BID ×7 days, then 5 mg BID) are first-line for hemodynamically stable PE. Non-inferior to VKA with reduced bleeding risk. Dabigatran and edoxaban require parenteral bridging.
Vitamin K antagonists (warfarin): Still used when DOACs are contraindicated (antiphospholipid syndrome, severe renal failure, certain drug interactions). Target international normalized ratio (INR) 2.0–3.0.

Systemic Thrombolysis

Indicated for massive PE with hemodynamic instability (SBP <90 mmHg, cardiac arrest, or obstructive shock). Alteplase 100 mg intravenous over 2 hours is the standard regimen. Contraindicated in patients with recent surgery (<3 weeks), active bleeding, prior hemorrhagic stroke, or intracranial neoplasm. Reduces short-term mortality and hemodynamic deterioration in massive PE at the cost of major bleeding (~9.2%) and intracranial hemorrhage (~1.5%).

For submassive PE, the PEITHO trial showed thrombolysis prevented hemodynamic decompensation but increased intracranial hemorrhage. In its 1,005 patients, death or hemodynamic collapse within 7 days occurred in 2.6% of those given the clot-dissolving drug tenecteplase with heparin versus 5.6% of those given placebo with heparin. Stroke occurred in 2.4% versus 0.2% (10 of the 12 strokes in the tenecteplase group were bleeding strokes), bleeding outside the skull in 6.3% versus 1.2%, and death by day 30 did not differ significantly (2.4% versus 3.2%). Thrombolysis in submassive PE is reserved for patients with significant RV dysfunction, elevated biomarkers, and low bleeding risk.

Catheter-Directed Therapy

Catheter-directed thrombolysis (CDT) or ultrasound-facilitated catheter-directed thrombolysis delivers lower-dose alteplase directly into the clot, potentially reducing systemic bleeding. Surgical embolectomy is reserved for massive PE refractory to thrombolysis or when thrombolytics are absolutely contraindicated. Catheter-directed mechanical thrombectomy (large-bore mechanical thrombectomy or computer-assisted vacuum thrombectomy) offers reperfusion without thrombolytics.

Supportive Care

Supplemental oxygen to maintain SpO2 >94%
Cautious fluid resuscitation (to limit RV volume overload)
Vasopressors (norepinephrine preferred) for hemodynamic support
Veno-arterial ECMO as bridge to definitive therapy in refractory massive PE
IVC filter placement only when anticoagulation is absolutely contraindicated or has failed

Duration of Anticoagulation

Provoked PE (transient risk factor): 3 months
Unprovoked PE: minimum 3 months; extended indefinitely in low bleeding-risk patients after shared decision-making
Cancer-associated VTE: LMWH or DOACs (edoxaban, rivaroxaban) for duration of malignancy or at least 6 months
Recurrent unprovoked VTE: indefinite anticoagulation

8. Complications

Chronic thromboembolic pulmonary hypertension (CTEPH): In a follow-up study of people with a first pulmonary embolism, symptomatic CTEPH developed in 1.0% by 6 months, 3.1% by 1 year and 3.8% by 2 years, with no new cases after 2 years; a previous pulmonary embolism (odds ratio 19.0), an unprovoked (idiopathic) pulmonary embolism (odds ratio 5.70), younger age and a larger perfusion defect raised the risk (Pengo 2004). Persistent obstruction leads to progressive pulmonary hypertension. Treated with surgical pulmonary endarterectomy, balloon pulmonary angioplasty, or riociguat.
Post-PE syndrome: Functional limitation, dyspnea, and reduced quality of life persisting beyond acute phase.
Right heart failure: Acute cor pulmonale with massive PE.
Paradoxical embolism: Arterial embolization via patent foramen ovale; causes stroke, limb ischemia.
Pulmonary infarction: Uncommon (~10%) due to dual pulmonary blood supply; may cause hemoptysis and pleuritis.
Recurrent VTE: Risk is ~5–10% per year without anticoagulation after unprovoked first PE.
Bleeding complications: Major hemorrhage from anticoagulation or thrombolytic therapy.

9. Prognosis

In-hospital mortality for all-comers with PE is approximately 7–11%, rising to 25–65% for massive PE with cardiogenic shock. The Pulmonary Embolism Severity Index (PESI) is the most validated prognostic tool:

Class I–II (low risk): 30-day mortality <3.6%. Eligible for outpatient or early discharge management.
Class III–V (high risk): 30-day mortality 3.2–24.5% (3.2–7.1% in class III, 4.0–11.4% in class IV, 10.0–24.5% in class V). Requires hospitalization and closer monitoring.

The simplified PESI (sPESI) uses six binary variables; a score of 0 identifies low-risk patients with <1% 30-day mortality. Intermediate-risk (submassive) PE carries 3–15% short-term mortality; elevated troponin and BNP, combined with RV dysfunction on imaging or echo, identifies the intermediate-high subgroup at greatest risk of deterioration.

Long-term mortality is predominantly driven by underlying comorbidities (cancer, cardiopulmonary disease) rather than PE itself in provoked events.

10. Prevention

Pharmacological thromboprophylaxis: UFH 5,000 units SC every 8–12 hours, LMWH, or fondaparinux in hospitalized medical and surgical patients at moderate-high VTE risk.
Mechanical prophylaxis: Graduated compression stockings, intermittent pneumatic compression devices — particularly when pharmacological agents are contraindicated.
Early ambulation: Post-operative mobilization within 24 hours significantly reduces VTE incidence.
Extended outpatient prophylaxis: After major orthopedic surgery (total hip/knee replacement, hip fracture), extended LMWH or rivaroxaban/apixaban for 28–35 days is recommended.
Risk stratification tools: Caprini Risk Assessment Model (surgical patients), Padua Prediction Score (medical patients) guide prophylaxis decisions.
Patient education: Hydration and leg exercises during prolonged air travel; compression stockings for high-risk travelers.
Limiting unnecessary immobility and prompt treatment of underlying hypercoagulable states are also part of prevention.

11. Recent Research and Advances

Pulmonary Embolism Response Teams (PERTs): Multidisciplinary teams involving pulmonology, hematology, cardiology, vascular surgery, and interventional radiology have been shown to improve decision-making and outcomes in intermediate- and high-risk PE. PERT utilization is associated with increased use of advanced therapies and reduced mortality.

Ultrasound-Facilitated Catheter-Directed Thrombolysis: The SEATTLE II and OPTALYSE PE trials demonstrated that ultrasound-assisted CDT achieves RV/LV ratio normalization with lower doses of alteplase compared to systemic thrombolysis, potentially reducing bleeding risk. Ongoing PE-TRACT trial is comparing CDT to anticoagulation alone in submassive PE.

Mechanical Thrombectomy: The FLARE and FLASH studies demonstrated safety and efficacy of large-bore mechanical thrombectomy for intermediate- and high-risk PE without thrombolytics. In the single-arm FLARE study of 106 patients with intermediate-risk PE, the right-to-left ventricle size ratio fell by an average of 25.1% at 48 hours, and 1 patient (1.0%) had major bleeding. Computer-assisted vacuum thrombectomy is another catheter method under study that removes clot without thrombolytic drugs.

PEERLESS Trial (2025): PEERLESS was the first randomized trial to compare two catheter treatments head to head, in 550 people with intermediate-risk PE: large-bore mechanical thrombectomy (clot removal through a wide catheter) versus catheter-directed thrombolysis (a clot-dissolving drug dripped through a catheter). Death, bleeding in the brain and major bleeding did not differ significantly. The clot-removal group had less clinical deterioration or need for bailout treatment (1.8% versus 5.4%), fewer intensive-care admissions after the procedure (41.6% versus 98.6%), shorter hospital stays (4.5 versus 5.3 nights) and fewer readmissions within 30 days (3.2% versus 7.9%); death at 30 days was similar (0.4% versus 0.8%). Many of the authors reported grants or fees from device makers.

Factor XI Inhibitors: Abelacimab, osocimab, and milvexian target Factor XIa, offering anticoagulation with potentially lower bleeding risk than current agents. Phase III trials in VTE are underway.

Artificial Intelligence in PE Diagnosis: AI algorithms applied to CTPA images can automatically detect PE, quantify thrombus burden, and assess RV strain with accuracy approaching expert radiologists, potentially accelerating diagnosis in emergency settings.

Key Research Papers

Konstantinides SV, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2020;41(4):543–603. — doi:10.1093/eurheartj/ehz405
Stevens SM, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline. Chest. 2021;160(6):e545–e608. — doi:10.1016/j.chest.2021.07.055
Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379(9828):1835–1846. — doi:10.1016/S0140-6736(11)61904-1
Meyer G, et al. (PEITHO Investigators). Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014;370(15):1402–1411. — doi:10.1056/NEJMoa1302097
Aujesky D, et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med. 2005;172(8):1041–1046. — doi:10.1164/rccm.200506-862OC
Piazza G, Hohlfelder B, Jaff MR, et al. A multicenter, randomized trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute intermediate-risk pulmonary embolism. JACC Cardiovasc Interv. 2015;8(10):1382–1392. — doi:10.1016/j.jcin.2015.04.020
Tapson VF, Sterling K, Jones N, et al. (OPTALYSE PE). Optimum Duration and Dose of Ultrasound-Facilitated Thrombolysis for Intermediate-Risk Pulmonary Embolism. JACC Cardiovasc Interv. 2018;11(14):1401–1410. — doi:10.1016/j.jcin.2018.04.008
Tu T, Toma C, Tapson VF, et al. A prospective, single-arm, multicenter trial of catheter-directed mechanical thrombectomy for intermediate-risk acute pulmonary embolism: the FLARE study. JACC Cardiovasc Interv. 2019;12(9):859–869. — doi:10.1016/j.jcin.2018.12.022
Jaber WA, Gonsalves CF, Stortecky S, et al. Large-bore mechanical thrombectomy versus catheter-directed thrombolysis in the management of intermediate-risk pulmonary embolism: primary results of the PEERLESS randomized controlled trial. Circulation. 2025;151(5):260–273. — doi:10.1161/CIRCULATIONAHA.124.072364
Jaff MR, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788–1830. — doi:10.1161/CIR.0b013e318214914f
Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83(3):416–420. — PubMed PMID: 10744147
Torbicki A, Galié N, Covezzoli A, et al. Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol. 2003;41(12):2245–2251. — doi:10.1016/s0735-1097(03)00479-0
Pengo V, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257–2264. — doi:10.1056/NEJMoa032274
Carrier M, Le Gal G, Wells PS, et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med. 2008;149(5):323–333. — doi:10.7326/0003-4819-149-5-200809020-00007
Righini M, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA. 2014;311(11):1117–1124. — doi:10.1001/jama.2014.2135
Tritschler T, et al. Venous Thromboembolism: Advances in Diagnosis and Treatment. JAMA. 2018;320(15):1583–1594. — doi:10.1001/jama.2018.14346

PubMed Topic Searches

The following PubMed topic searches surface the current peer-reviewed literature on Pulmonary Embolism. Each link opens a live PubMed query; results update as new papers are indexed.

Back to Table of Contents

Connections

Pulmonology
How Blood Clots Dissolve — Fibrinolysis & Clot-Busters — interactive animation
Pulmonary Hypertension
Deep Vein Thrombosis
Cancer
Chest Pain
Heart Failure
Vitamin K
Acute Respiratory Distress Syndrome
Shortness of Breath
Atrial Fibrillation
Stroke
Obesity
Thrombocytopenia
Coagulation Panel
Pneumonia
Interstitial Lung Disease
Vitamin D3
Omega-3 Fatty Acids
Edema
Varicose Veins
D-Dimer Test — the rule-out biomarker and its Wells, PERC and YEARS algorithms.
Pleural Effusion